XL765 (Synonyms: SAR245409; XL-765;SAR 245409;SAR- 245409) |
Catalog No.GC12336
One-Click Copy Product Info
|
PI3K/mTOR inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1123889-87-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
XL765 is a potent inhibitor of PI3Ks with IC50 values 39, 113,43,9 nM for p110α, β, δ, γ and 190, 908 nM for mTORC1, and mTORC2 respectively. [1]
The phosphoinositide-3 kinase (PI3K) pathway has been identified as an important target in breast cancer research. The PI3K pathway is integral to diverse cellular activities, including cellular metabolism and proliferation, survival, and differentiation. Besides, mTOR also acts as the nexus of signaling pathways regulating cell growth and proliferation. By inhibiting these targets, XL765 is thought to contribute to resistance to a variety of anticancer therapies. [2]
XL765 inhibits all four class I PI3K isoforms and mTOR with IC50 values in the nanomolar range in biochemical assays, whereas is highly selective against a panel of over 130 other human kinases. XL765 exhibits inhibition of PI3K-dependent production of the second messenger PIP3, and mTOR-dependent signaling stimulated by nutrient in cellular assays. Moreover, XL765 inhibits PI3K and mTOR-dependent phosphorylation of key components in the PI3K pathway including AKT, the substrates of AKT PRAS40 and GSK3β, p70S6K, the p70S6K substrate S6, and 4E-BP1 in diverse cancer cells. [1,3]
Treatment of XL765 to mice bearing xenografts of PIK3CA mutant MCF-7 breast adenocarcinoma cells or PTEN-deficient PC-3 prostate adenocarcinoma cells resulted in significant inhibition of PI3K and mTOR signaling. XL765 significantly decreased tumor growth or caused tumor shrinkage in different xenograft tumor models, including brain, lung, breast, ovarian, and prostate cancers which were correlated with inhibition of tumor cell proliferation and tumor angiogenesis, and with induction of apoptosis. However, rapamycin inhibited proliferation caused little or no induction of apoptosis. These results demonstrate that a dual inhibitor strategy, targeting both PI3K and mTOR, may offer significant advantages over specifically targeting the mTOR/Raptor complex. XL765 is currently undergoing a Phase I clinical trial in patients with solid tumors.[3]
References:
1.Braña I, LoRusso P, Baselga J, et al. A Phase 1 dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients with advanced malignancies[J]. bid, 2010, 16: 5.
2.Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer[J]. The oncologist, 2011, 16(Supplement 1): 12-19.
3.Laird A D. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR[J]. Molecular Cancer Therapeutics, 2007, 6(11 Supplement): B250-B250.
Cell experiment: | Cellular proliferation is assessed using the Cell Proliferation ELISA, Bromodeoxyuridine Chemiluminescence Kit. Cytotoxicity is assessed using the ATP Bioluminescence Assay as follows: PC-3, MCF7, A549, LS174T, MDA-MB-468, U87-MG, and OVCAR-3 cells are plated at densities of 7×103, 1.5×104, 6×103, 7×103, 7×103, 6×103, 1.5×104 cells per well, respectively, onto 96-well microtiter plates in culture medium, incubated at 37°C, 5% CO2 for 18 hours, and then treated with a serial dilution of compound in medium containing a final concentration of 0.3% DMSO. Triplicate wells are used for each compound concentration. Control wells receive 0.3% DMSO in media. Cultures are incubated at 37°C, 5% CO2 for an additional 24 hours and cells are then assayed for viability using the ViaLight HS Kit[2]. |
Animal experiment: | Mice[2] In vivo efficacy studies are performed in athymic nude mice. Tumor cells are cultured in DMEM supplemented with 10% FBS (20% for PC-3 and OVCAR-3 cells), Penicillin-Streptomycin, and nonessential amino acids at 37°C in a humidified 5% CO2 atmosphere. On day 0, cells are harvested by brief trypsinization, and 1 to 5×106 cells in 0.1 mL ice-cold Hanks Balanced Salt Solution are implanted subcutaneously (OVCAR-3) or intradermally (MCF7 and U-87 MG) into the hind flank of female athymic nude mice. In the case of the MCF7 model, an estrogen pellet (IRA) is implanted subcutaneously at the nape of neck at the time of tumor cell implantation. A total of 3×106 PC-3 cells are similarly harvested and implanted subcutaneously into the hind-flank of 5- to 8-week-old male nude mice. Tumor growth is monitored weekly with calipers until staging and dose initiation. During the dosing period, body and tumor weights are assessed. Voxtalisib (XL-765) is formulated in sterile water/10 mM HCl or water and administered at the indicated doses and regimens by oral gavage at a dose volume of 10 mL/kg. |
References: [1]. Garcia-Echeverria C, et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008 Sep 18;27(41):5511-26. | |
| Cas No. | 1123889-87-1 | SDF | |
| Synonyms | SAR245409; XL-765;SAR 245409;SAR- 245409 | ||
| Chemical Name | N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide | ||
| Canonical SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4N=C3NC5=CC(=CC(=C5)OC)OC)OC | ||
| Formula | C31H29N5O6S | M.Wt | 599.67 |
| Solubility | DMSO : 16 mg/mL (59.20 mM; Need ultrasonic and warming) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6676 mL | 8.3379 mL | 16.6758 mL |
| 5 mM | 333.5 μL | 1.6676 mL | 3.3352 mL |
| 10 mM | 166.8 μL | 833.8 μL | 1.6676 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)